These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8. Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061 [TBL] [Abstract][Full Text] [Related]
25. Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of Cap group. Zhang M; Ying JB; Wang SS; He D; Zhu H; Zhang C; Tang L; Lin R; Zhang Y J Cell Biochem; 2020 Jun; 121(5-6):3162-3172. PubMed ID: 31907955 [TBL] [Abstract][Full Text] [Related]
26. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket. Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062 [TBL] [Abstract][Full Text] [Related]
27. QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors. Cao GP; Thangapandian S; Son M; Kumar R; Choi YJ; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW Arch Pharm Res; 2016 Oct; 39(10):1356-1369. PubMed ID: 27542119 [TBL] [Abstract][Full Text] [Related]
28. Thiol versus hydroxamate as zinc binding group in HDAC inhibition: An ab initio QM/MM molecular dynamics study. Gong W; Wu R; Zhang Y J Comput Chem; 2015 Nov; 36(30):2228-35. PubMed ID: 26452222 [TBL] [Abstract][Full Text] [Related]
29. Exploring different classification-dependent QSAR modelling strategies for HDAC3 inhibitors in search of meaningful structural contributors. Jha T; Jana R; Banerjee S; Baidya SK; Amin SA; Gayen S; Ghosh B; Adhikari N SAR QSAR Environ Res; 2024 May; 35(5):367-389. PubMed ID: 38757181 [TBL] [Abstract][Full Text] [Related]
30. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants. Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148 [TBL] [Abstract][Full Text] [Related]
31. Discriminations of active from inactive HDAC8 inhibitors Part II: Bayesian classification study to find molecular fingerprints. Amin SA; Banerjee S; Adhikari N; Jha T SAR QSAR Environ Res; 2020 Apr; 31(4):245-260. PubMed ID: 32073312 [TBL] [Abstract][Full Text] [Related]
33. Potent non-hydroxamate inhibitors of histone deacetylase-8: Role and scope of an isoindolin-2-yl linker with an α-amino amide as the zinc-binding unit. Greenwood SOR; Chan AWE; Hansen DF; Marson CM Bioorg Med Chem Lett; 2020 Mar; 30(5):126926. PubMed ID: 31952961 [TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors. Huang WJ; Chen CC; Chao SW; Yu CC; Yang CY; Guh JH; Lin YC; Kuo CI; Yang P; Chang CI Eur J Med Chem; 2011 Sep; 46(9):4042-9. PubMed ID: 21712146 [TBL] [Abstract][Full Text] [Related]
35. Applying comparative molecular modelling techniques on diverse hydroxamate-based HDAC2 inhibitors: an attempt to identify promising structural features for potent HDAC2 inhibition. Yadav V; Banerjee S; Baidya SK; Adhikari N; Jha T SAR QSAR Environ Res; 2022 Jan; 33(1):1-22. PubMed ID: 34979835 [TBL] [Abstract][Full Text] [Related]
37. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies. Zhou H; Wang C; Deng T; Tao R; Li W J Biomol Struct Dyn; 2018 Jun; 36(8):1966-1978. PubMed ID: 28632421 [TBL] [Abstract][Full Text] [Related]
38. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Negmeldin AT; Knoff JR; Pflum MKH Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330 [TBL] [Abstract][Full Text] [Related]
39. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity. Heimburg T; Kolbinger FR; Zeyen P; Ghazy E; Herp D; Schmidtkunz K; Melesina J; Shaik TB; Erdmann F; Schmidt M; Romier C; Robaa D; Witt O; Oehme I; Jung M; Sippl W J Med Chem; 2017 Dec; 60(24):10188-10204. PubMed ID: 29190092 [TBL] [Abstract][Full Text] [Related]
40. Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget? Shen S; Kozikowski AP ChemMedChem; 2016 Jan; 11(1):15-21. PubMed ID: 26603496 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]